Literature DB >> 26851412

Early injury to cortical and cancellous bone from induction chemotherapy for adolescents and young adults treated for acute lymphoblastic leukemia.

E Orgel1, N M Mueske2, T A L Wren3, V Gilsanz4, A M Butturini5, D R Freyer5, S D Mittelman6.   

Abstract

Diminished bone density and skeletal fractures are common morbidities during and following therapy for acute lymphoblastic leukemia (ALL). While cumulative doses of osteotoxic chemotherapy for ALL have been reported to adversely impact bone density, the timing of onset of this effect as well as other changes to bone structure is not well characterized. We therefore conducted a prospective cohort study in pre-adolescent and adolescent patients (10-21years) newly diagnosed with ALL (n=38) to explore leukemia-related changes to bone at diagnosis and the subsequent impact of the first phase of chemotherapy ("Induction"). Using quantitative computerized tomography (QCT), we found that pre-chemotherapy bone properties were similar to age- and sex-matched controls. Subsequently over the one month Induction period, however, cancellous volumetric bone mineral density (vBMD) decreased markedly (-26.8%, p<0.001) with sparing of cortical vBMD (tibia -0.0%, p=0.860, femur -0.7%, p=0.290). The tibia underwent significant cortical thinning (average cortical thickness-1.2%, p<0.001; cortical area-0.4%, p=0.014), while the femur was less affected. Areal BMD (aBMD) concurrently measured by dual-energy X-ray absorptiometry (DXA) underestimated changes from baseline as compared to vBMD. Biochemical evidence revealed prevalent Vitamin D insufficiency and a net resorptive state at start and end of Induction. Our findings demonstrate for the first time that significant alterations to cancellous and cortical bone develop during the first month of treatment, far earlier during ALL therapy than previously considered. Given that osteotoxic chemotherapy is integral to curative regimens for ALL, these results provide reason to re-evaluate traditional approaches toward chemotherapy-associated bone toxicity and highlight the urgent need for investigation into interventions to mitigate this common adverse effect.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute lymphoblastic leukemia; Bone; Bone mineral density; Chemotherapy; DXA; QCT

Mesh:

Substances:

Year:  2016        PMID: 26851412      PMCID: PMC4795805          DOI: 10.1016/j.bone.2016.01.027

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  39 in total

1.  Incident Vertebral Fractures in Children With Leukemia During the Four Years Following Diagnosis.

Authors:  Elizabeth A Cummings; Jinhui Ma; Conrad V Fernandez; Jacqueline Halton; Nathalie Alos; Paivi M Miettunen; Jacob L Jaremko; Josephine Ho; Nazih Shenouda; Mary Ann Matzinger; Brian Lentle; David Stephure; Robert Stein; Ann Marie Sbrocchi; Celia Rodd; Bianca Lang; Sara Israels; Ronald M Grant; Robert Couch; Ronald Barr; John Hay; Frank Rauch; Kerry Siminoski; Leanne M Ward
Journal:  J Clin Endocrinol Metab       Date:  2015-07-14       Impact factor: 5.958

2.  Vitamin D metabolites and bone mineral density: The multi-ethnic study of atherosclerosis.

Authors:  Adriana J van Ballegooijen; Cassianne Robinson-Cohen; Ronit Katz; Michael Criqui; Matthew Budoff; Dong Li; David Siscovick; Andy Hoofnagle; Steven J Shea; Gregory Burke; Ian H de Boer; Bryan Kestenbaum
Journal:  Bone       Date:  2015-05-11       Impact factor: 4.398

3.  Bony morbidity in children treated for acute lymphoblastic leukemia.

Authors:  A J Strauss; J T Su; V M Dalton; R D Gelber; S E Sallan; L B Silverman
Journal:  J Clin Oncol       Date:  2001-06-15       Impact factor: 44.544

4.  Effect of chronic corticosteroid administration on diaphyseal and metaphyseal bone mass.

Authors:  T J Hahn; V C Boisseau; L V Avioli
Journal:  J Clin Endocrinol Metab       Date:  1974-08       Impact factor: 5.958

5.  Bone mineral density in children with acute lymphoblastic leukaemia.

Authors:  A M Boot; M M van den Heuvel-Eibrink; K Hählen; E P Krenning; S M de Muinck Keizer-Schrama
Journal:  Eur J Cancer       Date:  1999-11       Impact factor: 9.162

6.  CDC growth charts: United States.

Authors:  R J Kuczmarski; C L Ogden; L M Grummer-Strawn; K M Flegal; S S Guo; R Wei; Z Mei; L R Curtin; A F Roche; C L Johnson
Journal:  Adv Data       Date:  2000-06-08

7.  Altered mineral metabolism and bone mass in children during treatment for acute lymphoblastic leukemia.

Authors:  J M Halton; S A Atkinson; L Fraher; C Webber; G J Gill; S Dawson; R D Barr
Journal:  J Bone Miner Res       Date:  1996-11       Impact factor: 6.741

8.  Effects of intensive chemotherapy on bone and collagen turnover and the growth hormone axis in children with acute lymphoblastic leukemia.

Authors:  P M Crofton; S F Ahmed; J C Wade; R Stephen; M W Elmlinger; M B Ranke; C J Kelnar; W H Wallace
Journal:  J Clin Endocrinol Metab       Date:  1998-09       Impact factor: 5.958

9.  Altered bone mineral density and body composition, and increased fracture risk in childhood acute lymphoblastic leukemia.

Authors:  Inge M van der Sluis; Marry M van den Heuvel-Eibrink; Karel Hählen; Eric P Krenning; Sabine M P F de Muinck Keizer-Schrama
Journal:  J Pediatr       Date:  2002-08       Impact factor: 4.406

10.  Selective reduction in trabecular volumetric bone mineral density during treatment for childhood acute lymphoblastic leukemia.

Authors:  J A Kohler; R J Moon; R Sands; L J Doherty; P A Taylor; C Cooper; E M Dennison; J H Davies
Journal:  Bone       Date:  2012-07-05       Impact factor: 4.398

View more
  7 in total

1.  A randomized controlled trial testing an adherence-optimized Vitamin D regimen to mitigate bone change in adolescents being treated for acute lymphoblastic leukemia.

Authors:  Etan Orgel; Nicole M Mueske; Richard Sposto; Vicente Gilsanz; Tishya A L Wren; David R Freyer; Anna M Butturini; Steven D Mittelman
Journal:  Leuk Lymphoma       Date:  2017-02-20

2.  Myosteatosis in adolescents and young adults treated for acute lymphoblastic leukemia.

Authors:  Nicole M Mueske; Steven D Mittelman; Tishya A L Wren; Vicente Gilsanz; Etan Orgel
Journal:  Leuk Lymphoma       Date:  2019-07-02

3.  Sociodemographic and clinical characteristics associated with vitamin D status in newly diagnosed pediatric cancer patients.

Authors:  Paula Aristizabal; Michael Sherer; Bianca P Perdomo; Esteban Castelao; Courtney D Thornburg; James Proudfoot; Elizabeth Jacobs; Ron S Newfield; Peter Zage; William Roberts; Maria Elena Martinez
Journal:  Pediatr Hematol Oncol       Date:  2020-03-10       Impact factor: 1.969

4.  Switch to low-fat diet improves outcome of acute lymphoblastic leukemia in obese mice.

Authors:  Jonathan Tucci; Waseem Alhushki; Ting Chen; Xia Sheng; Yong-Mi Kim; Steven D Mittelman
Journal:  Cancer Metab       Date:  2018-11-01

5.  Bone morbidity in pediatric acute lymphoblastic leukemia.

Authors:  Moon Bae Ahn; Byung-Kyu Suh
Journal:  Ann Pediatr Endocrinol Metab       Date:  2020-03-31

6.  Is There an Association Between Bone Microarchitecture and Fracture in Patients who were Treated for High-grade Osteosarcoma? A Controlled Study at Long-term Follow-up Using High-resolution Peripheral Quantitative CT.

Authors:  Gerold Holzer; Gerhard Hobusch; Stinus Hansen; Lukas Fischer; Janina M Patsch
Journal:  Clin Orthop Relat Res       Date:  2021-11-01       Impact factor: 4.755

7.  Caloric and nutrient restriction to augment chemotherapy efficacy for acute lymphoblastic leukemia: the IDEAL trial.

Authors:  Etan Orgel; Celia Framson; Rubi Buxton; Jiyoon Kim; Gang Li; Jonathan Tucci; David R Freyer; Weili Sun; Matthew J Oberley; Christina Dieli-Conwright; Steven D Mittelman
Journal:  Blood Adv       Date:  2021-04-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.